Episode 35: Highlights From the AAN Annual Meeting

Author(s):

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Episode 35 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 35, "Highlights From the AAN Annual Meeting," features interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more.

EPISODE BREAKDOWN

1:50 – Nahas-Grieger on fremanezumab in migraine subpopulations

7:20 – Cree on inebilizumab treatment for NMOSD

14:45 – Somani on stroke rehabilitation disparities

19:45 – Fernandez on the MANAGE-PD tool

24:10 – Ontaneda on the classification of MS disease progression

31:15 – Gershon on the Mobile Toolbox Battery in tracking cognition

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Nahas S, Ning X, Cohen JM, Barash S, Campos VR, Silberstein SD. Efficacy of fremanezumab in patients with moderate and higher frequency episodic migraine. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.046
2. Nahas S, Jurgens TP, Kessler Y, et al. Cardiovascular safety of fremanezumab in patients with migraine and cardiovascular medical history or risk factors: A pooled analysis of phase 3 studies. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.034
3. Cree B, Bennett J, Weinshenker B, et al. Long-term efficacy outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.076
4. Cree B, Bennett J, Weinshenker B, et al. Long-term safety outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.100
5. Somani S, Nanavati H, Xiaohua Z, Lin C. African American women have lower functional performance during acute inpatient rehabilitation after intracerebral hemorrhagic strokes. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P5 073
6. Fernandez H, Odin P, Standaert D, et al. Identifying gaps in Parkinson disease patients eligible for device-aided therapies: results from using the MANAGE-PD tool in patients from G7 countries. Abstract P14.117
7. Ontaneda D, Qu J, McGinley M, et al. A Data Driven Approach to Define Disease Course Categories in MS. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.244
8. Pila S, Novak M, Weintraub S, et al. The Mobile Toolbox (MBT): A Completely Remote Platform for Cognitive Research. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P7.086